Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients

[1] Frappaz D(1992)Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study J Clin Oncol 10 1592-1601

[2] Michon J(1994)Carboplatin in pediatric malignancies Semin Oncol 21 65-76

[3] Hartmann O(1994)Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: a Pediatric Oncology Group study J Clin Oncol 12 1969-1973

[4] Bouffet E(1995)Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile J Clin Oncol 13 323-332

[5] Rubie H(2002)Dosing strategies for anticancer drugs: the good, the bad and the body-surface area Eur J Cancer 38 1677-1684

[6] Gentet JC(2006)Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations Clin Pharmacokinet 45 1077-1097

[7] Chastagner P(2008)Improving recruitment to clinical trials for cancer in childhood Lancet Oncol 9 392-399

[8] Sariban E(2001)Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy Clin Cancer Res 7 2205-2212

[9] Brugiere L(2007)Adaptive dosing and platinum-DNA adduct formation in children receiving high dose carboplatin for the treatment of solid tumours Br J Cancer 96 725-731

[10] Gaynon PS(1992)Disposition of antineoplastic agents in the very young child Br J Cancer 18 S23-S29

[1] Frappaz D(1992)Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study J Clin Oncol 10 1592-1601

[2] Michon J(1994)Carboplatin in pediatric malignancies Semin Oncol 21 65-76

[3] Hartmann O(1994)Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: a Pediatric Oncology Group study J Clin Oncol 12 1969-1973

[4] Bouffet E(1995)Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile J Clin Oncol 13 323-332

[5] Rubie H(2002)Dosing strategies for anticancer drugs: the good, the bad and the body-surface area Eur J Cancer 38 1677-1684

[6] Gentet JC(2006)Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations Clin Pharmacokinet 45 1077-1097

[7] Chastagner P(2008)Improving recruitment to clinical trials for cancer in childhood Lancet Oncol 9 392-399

[8] Sariban E(2001)Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy Clin Cancer Res 7 2205-2212

[9] Brugiere L(2007)Adaptive dosing and platinum-DNA adduct formation in children receiving high dose carboplatin for the treatment of solid tumours Br J Cancer 96 725-731

[10] Gaynon PS(1992)Disposition of antineoplastic agents in the very young child Br J Cancer 18 S23-S29